Mesoblast Limited
MESO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MESO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MESO
Mesoblast Limited is a biotechnology company focused on allogeneic cellular medicines for inflammatory diseases, with one FDA-approved product (Ryoncil®) for pediatric steroid-refractory acute graft-versus-host disease and several product candidates in clinical development.
Key risk: Ongoing operating losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials · 2 catalysts for Mesoblast Limited.
Mesoblast Limited is a biotechnology company focused on allogeneic cellular medicines for inflammatory diseases, with one FDA-approved product (Ryoncil®) for pediatric steroid-refractory acute graft-versus-host disease and several product candidates in clinical development.
- Mesoblast's first FDA-approved product, Ryoncil® (remestemcel-L), is approved in the U.S. for pediatric steroid-refractory acute graft-versus-host disease and was launched in March 2025 [sec · filed 2026-08-27].
- As of June 30, 2026, the company held total cash reserves of $102.9 million [sec · filed 2026-08-27].
- Net loss for the year ended June 30, 2026 was $57.5 million [sec · filed 2026-08-27].
- For the six months ended December 31, 2025, net product sales of Ryoncil® were $48.7 million [sec · filed 2026-02-27].
- As of December 31, 2025, accumulated losses since inception were $1,051.1 million [sec · filed 2026-02-27].
What works
- Mesoblast has one FDA-approved product (Ryoncil®) already generating revenue, with net product sales of $48.7 million in the six months ended December 31, 2025 [sec · filed 2026-02-27].
- The company secured a $125.0 million five-year non-dilutive credit-line facility in December 2025, providing additional financial flexibility [sec · filed 2026-02-27].
- Mesoblast is advancing a pipeline of product candidates for large indications including chronic low back pain and chronic heart failure [sec · filed 2026-08-27].
What to weigh
- Mesoblast has incurred operating losses since inception and expects to continue incurring substantial losses for the foreseeable future; net loss for the year ended June 30, 2026 was $57.5 million [sec · filed 2026-08-27].
- As of December 31, 2025, accumulated losses totaled $1,051.1 million, and the company may never achieve or sustain profitability [sec · filed 2026-02-27].
- Product revenues from Ryoncil® have not yet exceeded operating expenses, and the company faces risks related to commercial adoption, reimbursement, and manufacturing scale-up [sec · filed 2026-08-27].
From the filings
Quoted directly from source documents.
Ryoncil® is approved in the U.S. for pediatric SR-aGVHD and was launched in March 2025.
“Our first product approved by the United States Food and Drug Administration ("FDA"), Ryoncil ® (remestemcel-L), is approved only in the United States for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients of 2 months of age and older. We launched the product in March 2025”
SEC filings · August 27, 2026
Cash reserves as of June 30, 2026 were $102.9 million.
“As of June 30, 2026, we held total cash reserves of $102.9 million.”
SEC filings · August 27, 2026
Net loss for the year ended June 30, 2026 was $57.5 million.
“net loss for the year ended June 30, 2026 was $57.5 million.”
SEC filings · August 27, 2026
Net product sales of Ryoncil® were $48.7 million in the six months ended December 31, 2025.
“Since the launch of Ryoncil ® in late March 2025, we recognized net product sales of $48.7 million during the six months ended December 31, 2025.”
SEC filings · February 27, 2026
Catalyst timeline
- 2028-07-01 · Phase3_Topline · remestemcel-l-rknd — Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad — Topline data from a Phase 3 trial of remestemcel-L-rknd in adults with steroid-refractory acute graft-versus-host disease.
- 2028-07-01 · Phase3_Topline — Phase 3 Topline: A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and — Topline data from a second Phase 3 trial of remestemcel-L-rknd for a different indication.
Risks & what to watch (4)›
Key risks
- Ongoing operating losses — Mesoblast has incurred net losses since inception and expects to continue incurring substantial losses; net loss was $57.5M for FY2026 [sec · filed 2026-08-27].
- Accumulated deficit — As of Dec 31, 2025, accumulated losses were $1,051.1M; the company may never achieve profitability [sec · filed 2026-02-27].
- Commercialization risks — Ryoncil® revenues have not exceeded operating expenses; risks include reimbursement, formulary access, and manufacturing scale-up [sec · filed 2026-08-27].
- Clinical trial risks — Product candidates are evaluated in very ill patients; patient deaths or trial suspensions could harm commercial prospects [sec · filed 2026-08-27].
What to watch
- Topline results from the Phase 3 trial of remestemcel-L-rknd (Ryoncil®) in adults with steroid-refractory acute graft-versus-host disease, expected July 1, 2028 [catalyst block].
- Topline results from the Phase 3 trial evaluating remestemcel-L-rknd for another indication, expected July 1, 2028 [catalyst block].
- Progress of product candidates rexlemestrocel-L for chronic low back pain and chronic heart failure [sec · filed 2026-08-27].
- Ability to achieve profitability and manage cash burn, with cash of $102.9M as of June 30, 2026 [sec · filed 2026-08-27].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Mesoblast Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mesoblast Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
9.1 months
D/E 0.36
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~671d
30 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$70.2M
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 851,286 | $13.1M |
| susquehanna international group, llp | 714,572 | $11.0M |
| blackrock, inc. | 630,855 | $9.7M |
| citadel advisors llc | 545,359 | $8.4M |
| morgan stanley | 514,431 | $7.9M |
| goldman sachs group inc | 397,215 | $6.1M |
| bank of america corp /de/ | 100,004 | $1.5M |
| group one trading llc | 83,915 | $1.3M |
| m&g plc | 59,100 | $887K |
| lpl financial llc | 49,617 | $763K |
Showing top 10 of 66 institutional holders of Mesoblast Limited. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.3%
- Days to cover
- 10.4
- Shares short
- 3,049,603
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MESO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mesoblast Limited?
Mesoblast Limited is a biotechnology company focused on allogeneic cellular medicines for inflammatory diseases, with one FDA-approved product (Ryoncil®) for pediatric steroid-refractory acute graft-versus-host disease and several product candidates in clinical development.
What is Mesoblast Limited's next catalyst?
Mesoblast Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad" — expected July 1, 2028.
Who is the CEO of Mesoblast Limited?
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of Mesoblast Limited (MESO).
Where is Mesoblast Limited headquartered?
Mesoblast Limited (MESO) is headquartered in Melbourne, VIC, Australia.
What therapeutic areas does Mesoblast Limited focus on?
Mesoblast Limited develops therapies across Oncology, Gene Therapy, Immunology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.